Natural Product (NP) Details
| General Information of the NP (ID: NP9189) | |||||
|---|---|---|---|---|---|
| Name |
Pannarin
|
||||
| Synonyms |
Pannarin; Pannarine; NSC646008; 55609-84-2; NSC-646008; CHEMBL285415; 2-Chloro-3-hydroxy-8-methoxy-1,6,9-trimethyl-11-oxo-11H-dibenzo[b,e][1,4]dioxepine-4-carbaldehyde; DTXSID50204157; CHEBI:144185; BDBM50056915; 8-chloro-9-hydroxy-3-methoxy-1,4,7-trimethyl-6-oxobenzo[b][1,4]benzodioxepine-10-carbaldehyde; NCI60_015821; 11H-Dibenzo(b,e)(1,4)dioxepin-4-carboxaldehyde, 2-chloro-3-hydroxy-8-methoxy-1,6,9-trimethyl-11-oxo-; 8-chloro-9-hydroxy-3-methoxy-1,4,7-trimethyl-6-oxo-benzo[b][1,4]benzodioxepine-10-carbaldehyde
Click to Show/Hide
|
||||
| Species Origin | Pannaria tavaresii ... | Click to Show/Hide | |||
| Pannaria tavaresii | |||||
| Disease | Prostate cancer [ICD-11: 2C82] | Investigative | [1] | ||
| Structure |
|
Click to Download Mol2D MOL |
|||
| ADMET Property |
Absporption
Caco-2 Permeability
-5.101
MDCK Permeability
-4.795
PAMPA
- - -
HIA
- - -
Distribution
VDss
-0.432
PPB
98.7%
BBB
- - -
Metabolism
CYP1A2 inhibitor
+++
CYP1A2 substrate
- -
CYP2C19 inhibitor
++
CYP2C19 substrate
- - -
CYP2C9 inhibitor
++
CYP2C9 substrate
- - -
CYP2D6 inhibitor
- - -
CYP2D6 substrate
- - -
CYP3A4 inhibitor
- - -
CYP3A4 substrate
- - -
CYP2B6 inhibitor
- - -
CYP2B6 substrate
- - -
CYP2C8 inhibitor
+++
HLM Stability
+
Excretion
CLplasma
4.945
T1/2
0.849
Toxicity
DILI
++
Rat Oral Acute Toxicity
+
FDAMDD
+
Respiratory
+
Human Hepatotoxicity
+
Ototoxicity
- -
Drug-induced Nephrotoxicity
- -
Drug-induced Neurotoxicity
-
Hematotoxicity
-
Genotoxicity
-
Tips: 1. For the classification endpoints, the prediction probability values are transformed into six symbols: 0-0.1 (- - -), 0.1-0.3 (- -), 0.3-0.5 (-), 0.5-0.7 (+), 0.7-0.9 (++), and 0.9-1.0 (+++).
2. Additionally, the corresponding relationships of the three labels are as follows: excellent; medium; poor.
Click to Show/Hide
|
||||
| Click to Show/Hide the Molecular Information and External Link(s) of This Natural Product | |||||
| Formula |
C18H15ClO6
|
||||
| PubChem CID | |||||
| Canonical SMILES |
CC1=CC(=C(C2=C1OC3=C(C(=C(C(=C3C(=O)O2)C)Cl)O)C=O)C)OC
|
||||
| InChI |
1S/C18H15ClO6/c1-7-5-11(23-4)8(2)16-15(7)24-17-10(6-20)14(21)13(19)9(3)12(17)18(22)25-16/h5-6,21H,1-4H3
|
||||
| InChIKey |
LVGKNESDSKGROR-UHFFFAOYSA-N
|
||||
| CAS Number |
CAS 55609-84-2
|
||||
| ChEBI ID | |||||
| Herb ID | |||||
| Combinatorial Therapeutic Effect(s) Validated Clinically or Experimentally | ||||||
|---|---|---|---|---|---|---|
| α. A List of Drug(s) Whose Efficacy can be Enhanced by This NP | ||||||
| Clindamycin + Erythromycin + Gentamicin | Click to Show/Hide the Molecular Data of This Drug | |||||
| Achieving Therapeutic Synergy | Click to Show/Hide | |||||
| Representative Experiment Reporting the Effect of This Combination | [2] | |||||
| Detail(s) |
Combination Info
click to show the detail info of this combination
|
|||||
| In-vitro Model | Staphylococcus aureus | Microorganism model | Staphylococcus aureus | |||
| Experimental
Result(s) |
The natural compound pannarin might be a good candidate for the individualization of novel templates for the development of new antimicrobial agents or combinations of drugs for chemotherapy. | |||||